Sentence examples for multiple human tumours from inspiring English sources

Tissue factor is involved in pathological angiogenesis and is abnormally overexpressed in multiple human tumours and in tumour vascular endothelial cells but not in normal quiescent vascular endothelial cells (Contrino et al, 1996; Papetti and Herman, 2002).

The 8p22 region identified in our GBCs spans the FEZ1/LZTS1 gene, a candidate TSG, whose expression is altered in multiple human tumours (Ishii et al, 1999; Cabeza-Arvelaiz et al, 2001).

SEREX has been applied to multiple human tumours, including melanoma (Jager et al, 2000a), renal cell cancer (Scanlan et al, 1999), astrocytoma (Sahin et al, 1995), breast (Jager et al, 1999) and colon (Scanlan et al, 1998), identifying tumour antigens for each tumour type, indicating that a humoral response is elicited in the majority of cancer patients.

Importantly, HER2/neu overexpression has been previously reported to be associated with cancer cell proliferation, poor survival, and resistance to therapy in multiple human tumours (Slamon et al, 1987; Berchuck et al, 1990 , 1991 Hetzel et al, 1992; Santin et al, 2005).

Targeting SMOH through lentivector-mediated short hairpin RNA (shRNA) silencing mimics the effects of cyclopamine in multiple human tumour cells (Clement et al, 2007; Stecca et al, 2007; Varnat et al, 2009).

In an effort to identify a suitable VEGFR kinase inhibitor for clinical development, several potent VEGFR2 kinase inhibitors from indazolylpyrimidine series were tested in multiple human tumour xenograft models.

Interestingly, although there was a spectrum of dose-dependent antitumour activity ranging from dramatic tumour regression to de novo resistance when gefitinib was tested in multiple human tumour xenograft studies, the level of EGFR expression did not predict tumour response (Wakeling et al, 2002).

It is well documented that neoplastic cells derived from multiple human tumour types show an exaggerated capacity for haeme precursor synthesis following 5-ALA exposure relative to normal cells, although the exact contribution to tumour development remains unclear (Collaud et al, 2004).

Consistent with this hypothesis, blockade/modulation of the PD-L1/PD-1 and CTLA4 co-inhibitory pathways has already shown great promise for the treatment of multiple human solid tumours refractory/resistant to chemotherapy (Mellman et al, 2011).

First identified to be overexpressed in oesophageal carcinoma, and later in gastric cancer, FZD7 is now known to be overexpressed and correlated with aggressive phenotypes in multiple human solid tumours.

Human immuno-conjugate molecule (hI-con1) might therefore represent a fascinating new addition to the treatment of this aggressive disease and, potentially, multiple other human tumours overexpressing TF.